Keyphrases
FcRI
83%
Aggressive B-cell non-Hodgkin Lymphoma
83%
SF1126
83%
Vascular Permeability
83%
Cytokine Signaling
83%
Clinical Activity
83%
Mitogen-activated Protein Kinase
83%
PI3K Inhibitor
83%
Plasminogen Activator inhibitor-1 (PAI-1)
83%
Fibronectin
83%
Vascular Remodeling
83%
Joint Bleeding
83%
Gene-deficient Mice
83%
Reparative Process
83%
Hemostasis
83%
Brain Tumor
83%
Thrombosis
83%
Angiogenesis
83%
Endothelial Cell Migration
83%
Inflammatory Process
83%
Drug Design Strategies
83%
Cytokine Expression
83%
Pseudopalisading Necrosis
83%
Apoptosis
83%
Cell Cycle Arrest
83%
Pseudopalisades
66%
Vitronectin
48%
Pegylated Asparaginase
41%
Author Names
41%
Cell Proliferation
33%
Signaling Events
27%
Previous Knowledge
27%
Brain Pathology
27%
Brain Physiology
27%
Tumor Microenvironment
27%
Cytokine Receptor
27%
Cognate Ligand
27%
Stromal Microenvironment
27%
Space Constraints
27%
Cited References
27%
Activity in Vivo
27%
Therapeutic Modulation
27%
Therapeutic Action
27%
Work-as-done
27%
Tumor Therapeutics
27%
Intracellular Targeting
27%
Normal Brain
27%
Central Nervous System Tumors
27%
M-dependent
20%
Transcriptional Programming
20%
Bromodomain Inhibitors
20%
Immunosuppressive Macrophages
20%
U937 Cells
18%
Lymphoma Cells
16%
B-cell NHL
16%
Solid Tumors
16%
B-cell non-Hodgkin Lymphoma (B-NHL)
16%
SHIP1
16%
Rituximab
16%
Vaso-occlusive
16%
Vaso-occlusion
16%
Tumor Expansion
16%
Necrotic Foci
16%
Peripheral Expansion
16%
CAL-101
16%
Driver Pathway
16%
Human Brain Microvascular Endothelial Cells (HBMEC)
13%
Integrin
13%
Cell Adhesion
13%
Arthritic Score
13%
In Cancer
13%
Tyrosine Phosphorylation
9%
Signal Transduction
9%
Signaling Pathway
9%
Respiratory Burst
9%
Mobility Shift
9%
Protein Tyrosine Phosphorylation
9%
Kinase Activity
9%
Receptor Tyrosine Kinase
9%
In Vitro Kinase Assay
9%
Receptor Signaling
9%
Mechanism of Action
8%
Novel Therapeutics
8%
Prodrug
8%
IC50
8%
Cell Cycle Progression
8%
Lymphoma
8%
Human Tumors
8%
PI3K-Akt Pathway
8%
Dose Effect
8%
P110
8%
Clinical Trial Evaluation
8%
Glycogen Synthase Kinase 3 (GSK3)
8%
Early Phase Clinical Trials
8%
Akt Phosphorylation
8%
LY294002
8%
PI3K Pathway
8%
Cyclin D1 (CCND1)
8%
RGD Peptide
8%
Clinical Testing
8%
Biochemistry, Genetics and Molecular Biology
Eicosanoid Receptor
83%
Fc Receptor
83%
Cell Migration
83%
Phagocytosis
83%
Cytokine
83%
Plasminogen Activator Inhibitor-1
83%
Fibronectin
83%
Angiogenesis
83%
Mitogen-Activated Protein Kinase
83%
Ibrutinib
83%
BRD4
83%
Receptor Tyrosine Kinase
50%
Kinase
50%
Phosphotransferase
50%
Vitronectin
48%
Cross-Link
33%
Tyrosine Phosphorylation
33%
Signal Transduction
33%
Hemocyte
33%
Heterologous Expression
33%
Protein Tyrosine Phosphatase
33%
Cytokine Receptor
27%
Tyrosine
16%
Respiratory Burst
16%
Phosphoinositide 3-Kinase
16%
Macrophage
16%
Dephosphorylation
16%
Wild Type
16%
Phosphoprotein
16%
Cell Cycle Arrest
16%
Antineoplastic Activity
16%
Mammalian Target of Rapamycin
16%
Immunoglobulin M
16%
Integrin
13%
Cell Adhesion
13%
N-Terminus
6%
Pharmacology, Toxicology and Pharmaceutical Science
Nonhodgkin Lymphoma
100%
Malignant Neoplasm
100%
Neoplasm
91%
Immunotherapy
83%
Ibrutinib
83%
[1 (4 Oxo 8 Phenyl 4h 1 Benzopyran 2 Yl)morpholinio]methoxysuccinylarginylglycylaspartylserine Acetate
83%
Mantle Cell Lymphoma
83%
Receptor
83%
Drug Development
83%
Mitogen Activated Protein Kinase
83%
DBA 1 Mouse
83%
Phosphotransferase
50%
Preclinical Study
20%
Immune Checkpoint Inhibitor
20%
Immunogenicity
20%
Melanoma
20%
Chemotherapy
20%
Clinical Study
20%
Immunoglobulin M
16%
Solid Malignant Neoplasm
16%
Antitumor Activity
16%
Phosphoprotein
16%
Rituximab
16%
Protein Tyrosine Kinase
16%
Protein P72
16%
Glycogen Synthase Kinase
8%
Clinical Trial
8%
Prodrug
8%
IC50
8%
2 Morpholino 8 Phenylchromone
8%
Leukemia
8%
Cyclin D1
8%